216
Participants
Start Date
July 19, 2018
Primary Completion Date
January 5, 2024
Study Completion Date
April 13, 2027
Osimertinib 80mg/40mg
The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
Placebo Osimertinib 80mg/40mg
"The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met"
Research Site, San Isidro
Research Site, Taichung
Research Site, Budapest
Research Site, Budapest
Research Site, Ciudad Autónoma de Bs. As.
Research Site, Rosario
Research Site, Gyöngyös - Mátraháza
Research Site, San Salvador de Jujuy
Research Site, Ankara
Research Site, Mar del Plata
Research Site, Pécs
Research Site, Taipei
Research Site, Bangkok
Research Site, Bangkok
Research Site, Bangkok
Research Site, George Town
Research Site, Bangkok
Research Site, New Delhi
Research Site, Taipei
Research Site, Seongnam-si
Research Site, San Sebastián
Research Site, Incheon
Research Site, Madrid
Research Site, Madrid
Research Site, Cheongju-si
Research Site, Málaga
Research Site, Atlanta
Research Site, Istanbul
Research Site, Istanbul
Research Site, Izmir
Research Site, Khon Kaen
Research Site, Taichung
Research Site, Taichung
Research Site, Seville
Research Site, Valencia
Research Site, Kuala Selangor
Research Site, Mueang
Research Site, Lampang
Research Site, Madison
Research Site, Adapazarı
Research Site, Kuala Lumpur
Research Site, Ho Chi Minh City
Research Site, Tainan City
Research Site, Kaohsiung City
Research Site, Salt Lake City
Research Site, Hat Yai
Research Site, Duarte
Research Site, Mérida
Research Site, Hanoi
Research Site, Hà Nội
Research Site, Beijing
Research Site, Beijing
Research Site, New Delhi
Research Site, New Delhi
Research Site, Moscow
Research Site, Gūrgaon
Research Site, Changchun
Research Site, Kostroma
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Shanghai
Research Site, Shanghai
Research Site, Obninsk
Research Site, Jinan
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Linhai
Research Site, Karamsad
Research Site, Changsha
Research Site, Kazan'
Research Site, Nashik
Research Site, Wuhan
Research Site, Wuhan
Research Site, Ufa
Research Site, Guangzhou
Research Site, Bangalore
Research Site, Hubli
Research Site, Chengdu
Research Site, Novisibirsk
Research Site, Ho Chi Minh City
Research Site, Kolkata
Research Site, Ürümqi
Research Site, Florham Park
Research Site, Ciudad Autónoma de Bs. As.
Research Site, Barretos
Research Site, Curitiba
Research Site, Florianópolis
Research Site, Fortaleza
Research Site, Porto Alegre
Research Site, Porto Alegre
Research Site, Ribeirão Preto
Research Site, São Paulo
Research Site, São Paulo
Research Site, Hiroshima
Research Site, Kanazawa
Research Site, Kashiwa
Research Site, Nagoya
Research Site, Niigata
Research Site, Osaka
Research Site, Sakaishi
Research Site, Sapporo
Research Site, Sayama
Research Site, Sendai
Research Site, Shinjuku-ku
Research Site, Sunto-gun
Research Site, Yokohama
Research Site, Lima
Research Site, Lima
Research Site, Lima
Research Site, Lima
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Taoyuan District
Research Site, Adana
Research Site, Ankara
Research Site, Ankara
Lead Sponsor
AstraZeneca
INDUSTRY